These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 26317978)

  • 1. The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
    Dalgard O; Martinot-Peignoux M; Verbaan H; Bjøro K; Ring-Larsen H; Marcellin P
    PLoS One; 2015; 10(8):e0120866. PubMed ID: 26317978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
    Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
    Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin.
    Nakaya M; Enomoto M; Fujii H; Kobayashi S; Iwai S; Morikawa H; Tamori A; Sakaguchi H; Kawada N
    Osaka City Med J; 2013 Dec; 59(2):79-89. PubMed ID: 24575583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
    J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
    J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
    Dalgard O; Bjoro K; Ring-Larsen H; Verbaan H
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):552-6. PubMed ID: 20154627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Ferraro D; Giglio M; Bonura C; Di Marco V; Mondelli MU; Craxì A; Di Stefano R
    J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Gilles L; De Locht P; Picchio G; De Meyer S; Sarrazin C
    J Clin Virol; 2015 Nov; 72():133-40. PubMed ID: 26513763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
    Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
    J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
    Desombere I; Van Vlierberghe H; Couvent S; Clinckspoor F; Leroux-Roels G
    J Clin Microbiol; 2005 Jun; 43(6):2590-7. PubMed ID: 15956369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
    Ogawa K; Hige S; Nakanishi M; Yamamoto Y; Chuma M; Nagasaka A; Asaka M
    Antivir Ther; 2009; 14(4):513-22. PubMed ID: 19578236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
    Knop V; Teuber G; Klinker H; Möller B; Rasenack J; Hinrichsen H; Gerlach T; Spengler U; Buggisch P; Neumann K; Sarrazin C; Zeuzem S; Berg T
    Ann Hepatol; 2013; 12(2):190-8. PubMed ID: 23396729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily.
    Sentjens RE; Weegink CJ; Beld MG; Cooreman MC; Reesink HW
    Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):833-40. PubMed ID: 12172402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.